Close Menu

NEW YORK – HTG Molecular Diagnostics reported after the close of the market on Tuesday that its third quarter revenues dropped 67 percent year over year, primarily to due the impact of the COVID-19 pandemic.

For the three months ended Sept. 30, the Tucson, Arizona-based firm reported revenues of $1.8 million compared to $5.4 million in the same period the year before, missing the Wall Street estimate of $2.2 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Bloomberg reports AstraZeneca may conduct another study of its candidate SARS-CoV-2 vaccine after dosing error.

Moderna is applying for an Emergency Use Authorization for its coronavirus vaccine, according to the New York Times.

The National Health Service is to conduct a trial of Grail's blood-based screening test for cancer.

In PLOS this week: somatic mutation patterns of glioblastomas among Lebanese patients, phenome-wide study using UK Biobank data, and more.

Dec
03
Sponsored by
Mission Bio

Recent work by many investigators has discovered that over the course of aging, hematopoietic stem cells (HSCs) commonly undergo clonal expansion.